Local Treatment of Rectal Cancer

2014 ◽  
pp. 285-289
Author(s):  
Niels Qvist
Keyword(s):  
Rectal Cancer ◽  
Local Treatment

Addition of Oxaliplatin to Continuous Fluorouracil, l-Folinic Acid, and Concomitant Radiotherapy in Rectal Cancer: The Lyon R 97-03 Phase I Trial

2001 ◽  
Vol 19 (9) ◽  
pp. 2433-2438 ◽  
Author(s):  
Gilles Freyer ◽  
Nadine Bossard ◽  
Pascale Romestaing ◽  
Françoise Mornex ◽  
Olivier Chapet ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Phase I ◽  
Folinic Acid ◽  
Dose Level ◽  
Dose Escalation ◽  
Local Treatment ◽  
Rectal Adenocarcinoma ◽  
Severe Diarrhea ◽  
Phase Ii Studies ◽  
Level 1

PURPOSE: Oxaliplatin could increase the efficacy of fluorouracil (5-FU)/folinic acid chemoradiotherapy in rectal cancer. We tested three dose levels to identify a feasible oxaliplatin dose for combination therapy. PATIENTS AND METHODS: Between February 1998 and April 2000, we included 17 rectal adenocarcinoma patients in a single-center phase I study. Patients had T4 rectal carcinoma, T1-T3 disease with colostomy refusal, or potentially operable T2/T3 M1 requiring local treatment. Pelvic radiotherapy was 45 Gy over 5 weeks, 1.8 Gy/fraction, with concomitant chemotherapy weeks 1 and 5. Chemotherapy was oxaliplatin 80, 100, or 130 mg/m2 2-hour infusion on day 1 followed by l-folinic acid 100 mg/m2/d intravenous bolus, and 5-FU 350 mg/m2/d continuous infusion on days 1 to 5 (FolfoR1). Six patients refusing surgery received additional contact radiotherapy +/− brachytherapy. Dose escalation proceeded if less than two of six patients had dose-limiting toxicity (DLT) at a given dose-level. RESULTS: All except two patients completed treatment; patients at level 1 (prolonged grade 1 thrombocytopenia) and level 3 (prolonged cold-related dysesthesia) had no second chemotherapy course. Median follow-up is 14 months (range, 2 to 28 months). One elderly patient at dose level 1 had DLT asthenia, severe diarrhea and vomiting, and more than 10% weight loss. There were no other DLTs and no severe rectitis or gastrointestinal toxicity. There were objective responses at all doses and no progressions. Eight patients underwent radical surgery after chemoradiotherapy. Two had complete pathologic responses. CONCLUSION: FolfoR1 seems feasible and effective. Dose escalation did not increase toxicity. Although the MTD was not reached in this study, we recommend oxaliplatin 130 mg/m2 for phase II studies because it is the dose determined from studies in metastatic patients with no toxicity when given concurrently with radiation.

Contact therapy: A feasible option for local treatment of rectal cancer in non-operable patients—A Danish experience.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14543-e14543
Author(s):  
Karen-Lise Garm Spindler ◽  
Peter Rasmussen ◽  
Irina Kryglikova ◽  
Lars Nyvang ◽  
Anni Ravnsbæk Jensen ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Local Treatment ◽  
Feasible Option ◽  
Danish Experience

scholarly journals What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation?

2014 ◽  
Vol 40 (1) ◽  
pp. 60-67 ◽  
Author(s):  
Roel C.J. Schlijper ◽  
Janneke P.C. Grutters ◽  
Ruud Houben ◽  
Anne-Marie C. Dingemans ◽  
Joachim E. Wildberger ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Radiofrequency Ablation ◽  
Lung Metastases ◽  
Local Treatment ◽  
Cancer Surgery ◽  
Rectal Cancer Surgery

Local Treatment of Rectal Cancer

2000 ◽  
pp. 187-203
Author(s):  
Julio Garcia-Aguilar ◽  
Charles O. Finne
Keyword(s):  
Rectal Cancer ◽  
Local Treatment

Minimal invasive surgery in the local treatment of rectal cancer

1991 ◽  
Vol 6 (2) ◽  
pp. 77-81 ◽  
Author(s):  
G. Buess ◽  
B. Mentges ◽  
K. Manncke ◽  
M. Starlinger ◽  
H. D. Becker
Keyword(s):  
Rectal Cancer ◽  
Invasive Surgery ◽  
Minimal Invasive Surgery ◽  
Local Treatment ◽  
Minimal Invasive

Organ Preservation for Rectal Cancer

2007 ◽  
Vol 25 (8) ◽  
pp. 1014-1020 ◽  
Author(s):  
Nancy N. Baxter ◽  
Julio Garcia-Aguilar
Keyword(s):  
Rectal Cancer ◽  
Local Recurrence ◽  
Local Excision ◽  
Organ Preservation ◽  
Local Treatment ◽  
Radical Resection ◽  
Population Based ◽  
Sphincter Preservation ◽  
T2 Lesions ◽  
Intestinal Continuity

Organ preservation with maintenance of function in the treatment of rectal cancer is highly valued by patients. Although most patients with resectable rectal cancer can undergo a sphincter-sparing radical procedure, there are patient, tumor, surgeon, and treatment factors that influence the ability to restore intestinal continuity after radical resection. Although population-based data suggest that the rate of sphincter preservation is lower than could be obtained at expert centers, there are patients in whom low anterior resection with colo-anal anastomosis is not technically feasible and/or oncologically sound. Additionally, resection with ultralow anastomosis results in functional compromise in many patients. Local treatment of rectal cancer aims to decrease the morbidity and the functional sequelae associated with radical resection; however, local excision is associated with a higher rate of local recurrence than is radical resection. Strict selection criteria are essential when considering local excision, and patients should be informed of the risk of local recurrence. The use of adjuvant therapy with local excision, particularly in patients with T2 lesions, has promise but should be considered only as part of a clinical trial.

scholarly journals Local Treatment for Rectal Cancer

2007 ◽  
Vol 20 (3) ◽  
pp. 182-189 ◽  
Author(s):  
Daniel Geisler
Keyword(s):  
Rectal Cancer ◽  
Local Treatment
Sign in / Sign up

Export Citation Format

Share Document